Summary of Continuum Therapeutics (CTNM) 2025 Conference Call Company Overview - Continuum Therapeutics is a San Diego-based biotech company focused on neuroscience, inflammation, and immunology [3][4] - The company has two clinical-stage assets and is pursuing multiple therapeutic areas with important clinical proof of concept readouts expected [4] Key Programs PIPE-791 - PIPE-791 is a first-in-class selective inhibitor of the LPA1 receptor, currently in development for idiopathic pulmonary fibrosis (IPF) [5][16] - The unmet need in IPF is significant, with approximately 130,000 patients in the US and 3 million worldwide, and existing treatments are considered suboptimal [7][8] - Current treatments, such as Nintendonib and Prophenidone, have tolerability issues leading to high dropout rates [15] - The LPA1 receptor is linked to fibrosis and inflammation, making it a critical target for IPF treatment [16][17] - Continuum believes that PIPE-791 has a unique pharmacokinetic (PK) profile that allows for high target coverage and improved tolerability compared to existing therapies [21][25] PIPE-307 - PIPE-307 is a muscarinic receptor antagonist being evaluated in relapse and remitting multiple sclerosis (MS) [49] - The program is based on prior studies that demonstrated the potential for muscarinic receptor antagonism to improve remyelination [51] - The Phase II study is designed to measure low contrast letter acuity and other functional biomarkers [57] Clinical Development and Strategy - Continuum plans to initiate a global Phase II proof of concept study for PIPE-791 in the fourth quarter, with a focus on safety, tolerability, and efficacy [30][31] - The company is also conducting a PET receptor occupancy study to validate dosing for PIPE-791 [34][36] - The chronic pain program is exploratory, focusing on osteoarthritis and chronic lower back pain, with a small Phase Ib study planned [39][45] Market Landscape - The IPF treatment market is viewed as an untapped opportunity, with existing therapies generating significant sales despite their limitations [29] - Continuum anticipates that a safer and more effective drug could carve out a significant space in the IPF treatment landscape, which is currently lacking in effective options [27][28] Upcoming Catalysts - Key upcoming catalysts include the pain study readout in the first half of next year and the initiation of the IPF study [47] - The company is also monitoring BMS' top-line data, expected in the second half of next year, as a benchmark for its own programs [48] Conclusion - Continuum Therapeutics is positioned to address significant unmet needs in IPF and MS with its innovative drug candidates, backed by a robust clinical development strategy and a focus on improving patient outcomes through enhanced tolerability and efficacy [64]
Contineum Therapeutics (CTNM) 2025 Conference Transcript